Chemomab Therapeutics Ltd (STU:2QV0)
€ 1.68 0.1 (6.33%) Market Cap: 29.80 Mil Enterprise Value: 11.80 Mil PE Ratio: 0 PB Ratio: 1.92 GF Score: 33/100

Chemomab Therapeutics Ltd at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2023 / 01:20PM GMT
Release Date Price: €1.32 (+1.54%)
Jeff Jones
Oppenheimer - Analyst

Good morning, everyone, and welcome as we continue with day three of Oppenheimer's 33rd Annual Healthcare Conference. I'm Jeff Jones, a senior analyst here on the biotechnology team, and I'm delighted to welcome the Chemomab team with Dale Pfost, CEO as the lead presenter but we have the whole team here.

Dale, I will hand it off to you to take us through the Chemomab store.

Dale Pfost
Chemomab Therapeutics Ltd. - Chairman & CEO

Thank you. Today, I'll be joined by Adi Mor, our co-founder and CSO; Matt Frankel, our CMO; Don Marvin, our EVP, COO, and CFO; and Barbara Lindheim, our VP of Strategic Communications. Please refer to our forward-looking statements and risk factors, including those on file with the SEC.

Here's why we are so excited about Chemomab, in four key points we'll be covering today. We have a unique target with disease-modifying potential. We've worked towards de-risking our programs through nearly 10 years of extensive preclinical studies, reinforced by four completed clinical trials. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot